FRANCES SPARKS: Open Payments
NPI 1255056370 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 54 payments from 17 companies in 2025. Trend: 2023 $611 · 2024 $954 · 2025 $893
Food & beverage: $860Education: $32
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $191 |
| AstraZeneca Pharmaceuticals LP | 8 | $144 |
| Novo Nordisk Inc | 6 | $121 |
| Lilly USA, LLC | 4 | $69 |
| PFIZER INC. | 4 | $63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $57 |
| GlaxoSmithKline, LLC. | 3 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
Products named: OTEZLA, Ozempic, BREZTRI, MOUNJARO, XIFAXAN, NURTEC ODT, REPATHA, FARXIGA.
Industry payments across KY — which companies pay providers there.
